WO2003091689A2 - Bis-transition-metal-chelate-probes - Google Patents
Bis-transition-metal-chelate-probes Download PDFInfo
- Publication number
- WO2003091689A2 WO2003091689A2 PCT/US2002/036180 US0236180W WO03091689A2 WO 2003091689 A2 WO2003091689 A2 WO 2003091689A2 US 0236180 W US0236180 W US 0236180W WO 03091689 A2 WO03091689 A2 WO 03091689A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chelator
- functionalized
- mono
- fluorescence
- molecule according
- Prior art date
Links
- 0 C**(C*(O1)O2)(CC1=O)CC2=O Chemical compound C**(C*(O1)O2)(CC1=O)CC2=O 0.000 description 5
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
Definitions
- This invention relates to compositions and methods for labeling molecules. More particularly, the present invention relates to certain transition metal chelate probes capable of selectively associating with histidine- containing target sequences on compounds of interest and yielding a detectable signal.
- Characterization of proteins often requires the ability to incorporate detectable groups—e.g., fluorochromes, chromophores, spin labels, radioisotopes, paramagnetic atoms, heavy atoms, haptens, crosslinking agents, and cleavage agents— at specific, defined sites.
- detectable groups e.g., fluorochromes, chromophores, spin labels, radioisotopes, paramagnetic atoms, heavy atoms, haptens, crosslinking agents, and cleavage agents.
- site-specific labeling can be accomplished by use of site-directed mutagenesis to introduce a cysteine residue at the site of interest, followed by cysteine-specific chemical modification to incorporate the labeled probe.
- site-specific labeling is difficult.
- Strategy (i)-(iii) do not permit in situ labeling (i.e., direct labeling of proteins in cuvettes, gels, blots, or biological samples— without the need for a subsequent purification step) or in vivo labeling (i.e., direct labeling of proteins in cells).
- Strategy (iv) requires a structural scaffold presenting two trivalent-arsenic atoms in a precisely defined spatial relationship and therefore relates only to a limited number of detectable groups (such as those having a detectable xanthene, xanthanone, or phenoxazinestructural nucleus).
- Transition-metal chelates consisting of a transition-metal ion, such as Ni 2+ , Co 2+ , Cu + , or Zn 2+ , in complex with a tridentate or tetradentate chelating ligand, such as iminodiacetic acid (IDA) or nitrilotriacetic acid (NT A), exhibit high affinity for oligohistidine sequences, particularly hexahistidine sequences (Sulkowski, E., Trends Biotechnol., 3:1-7 (1985); Hochuli, et al., J. Chromat. 411:177-184 (1987); Hochuli, E. et al. BioTechnol. 6:1321-1325 (1988).
- Figure 1 shows a proposed model for binding of neighboring hexahistidine residue to a Ni-NTA resin as disclosed in Crowe, J. et al., Methods Mol. Biol, 31:371-387 (1994)).
- immobilized-metal- chelate affinity chromatography a transition-metal chelate consisting of a transition-metal ion, such as Ni 2+ , Co 2+ , Cu 2+ , or Zn 2+ , in complex with a tridentate or tetradentate chelating ligand, such as iminodiacetic acid (IDA) or nitrilotriacetic acid (NT A), is immobilized on a solid phase, such as chromatographic resin, and the resulting immobilized metal chelate is used to bind, and thereby purify from other components, tagged biomolecules.
- IDA iminodiacetic acid
- NT A nitrilotriacetic acid
- a transition-metal chelate consisting of a transition-metal ion, such as Ni 2+ , Co 2+ , Cu + , or Zn 2+ , in complex with a tridentate or tetradentate chelating ligand, such as iminodiacetic acid (IDA) or nitrilotriacetic acid (NTA), is immobilized on a biosensor chip, such a surface-plasmon-resonance biosensor chip, and the resulting immobilized metal chelate is used to detect, quantify, and analyze tagged biomolecules.
- IDA iminodiacetic acid
- NTA nitrilotriacetic acid
- the invention provides a molecule with two pendant metal-chelate moieties according to the general structural Formula (I), including tautomers, salts, and acids thereof:
- Y and Y' are each a transition metal, (b) R 1 and R 1 are each independently C(COO " ), CH(COOH), or absent; (c) R 2 and R 2 are linkers each having a length of from about 3.0 to about 20 A; and (d) X is a detectable group.
- the linkers may be linear or branched, may contain aromatic moieties, and optionally may be further substituted.
- a xanthene, xanthanone, or phenoxazine detectable group involving reaction of a xanthene, xanthanone, or phenoxazine detectable group, a secondary-amine derivative of a chelator, and formaldehyde, according to the Mannich reaction (Mannich, C. et al. Arch. Pharm. 250:647, 1912); followed by addition of a transition metal.
- a labeled target material including a target sequence of the form: (H)j, wherein H is histidine, and i is 4 to 12, preferably 4 to 8, and most preferably 6, and wherein the target sequence is bonded with a molecule according to Formula (I).
- detectable complex including a molecule according to Formula (I) and a target sequence, bonded thereto.
- the target sequence includes an amino acid sequence of the form: (H)bond wherein H is histidine, and i is 4 to 12, preferably 4 to 8, and most preferably 6.
- the invention also includes a method for imparting fluorescent properties to a target material, including the step of reacting: (a) the target material having a target sequence of the form (H) terme wherein H is histidine, and i is 4 to 12, preferably 4 to 8, and most preferably 6, with (b) a molecule according to Formula (I), under conditions sufficient to permit metal- chelate moieties of said molecule according to Formula (I) to bond to the target sequence.
- a method for detecting a target material of interest including the steps of: (a) providing a target material of interest having a target sequence of the form: (H)band wherein H is histidine, and i is 4 to 12, preferably 4 to 8, and most preferably 6; (b) incubating the polypeptide with a molecule according to Formula (I), having a detectable group, for a time period sufficient to allow labeling of the target material; and (c) detecting the detectable group, thereby detecting the target material of interest.
- a method for imaging the localization, concentration or interactions of a target material of interest on or within cells, tissues, organs or organisms including the steps of: (a) providing a target material of interest having a target sequence of the form: (H) choir wherein H is histidine, and i is 4 to 12, preferably 4 to 8, and most preferably 6; (b) incubating the target material with a molecule according to Formula (I) for a time period sufficient to allow labeling of the polypeptide; and (c) detecting the detectable group of said molecule according to Formula (I), thereby imaging the localization, concentration or interactions of the target material of interest.
- an assay method for monitoring a binding process including the steps of: (a) reacting a first component of a specific binding pair with a second component of the pair, with the first component being labeled with a molecule according to Formula (I) having a detectable group; and (b) monitoring the reaction by monitoring a change in a signal of the detectable group.
- an assay method for monitoring a binding process including the steps of: (a) reacting a first component of a specific binding pair with a second component of the pair, with the first component being labeled with a molecule according to Formula (I) having a detectable group; and (b) monitoring the reaction by monitoring fluorescence emission intensity, fluorescence lifetime, fluorescence polarization, fluorescence anisotropy, or fluorescence correlation of the detectable group.
- an assay method for monitoring a binding process including the steps of: (a) reacting a first component of a specific binding pair with a second component of the pair, with the first component being labeled with a molecule according to Formula (I) wherein X of Formula (I) is a fluorochrome, and with the second component containing Y, wherein Y is selected from the group including a fluorochrome and chromophore, Y being capable of participating in fluorescence energy transfer, fluorescence quenching, or exciton formation with X; and (b) monitoring the reaction by monitoring fluorescence of X.
- the invention also provides an assay method for monitoring a binding process, including the steps of: (a) reacting a first component of a specific binding pair with a second component of the pair, with the first component being labeled with a molecule according to Formula (I) wherein X of Formula (I) is selected from the group consisting of a fluorochrome and a chromophore, and with the second component containing Y, wherein Y is a fluorochrome able to participate in fluorescence energy transfer, fluorescence quenching, or exciton formation with X; and (b) monitoring the reaction by monitoring fluorescence of Y.
- the invention further provides an assay method for monitoring a reaction, including the steps of: (a) reacting a first participant in a reaction with a second participant in the reaction, the first participant being labeled with a molecule according to Formula (I); and (b) monitoring the reaction by monitoring a change in a detectable property of the detectable group.
- a method for isolating a target material of interest including the steps of: (a) contacting molecules according to Formula (I) immobilized on a solid support, with a solution containing a polypeptide of interest, the polypeptide including a target sequence of the form: (H) choir wherein H is histidine, and i is 4 to 12, preferably 4 to 8, and most preferably 6, under conditions that allow binding of the target material to immobilized molecules of Formula (I); and (b) eluting the target material of interest with a low-molecular weight monothiol or low-molecular-weight dithiol.
- the invention also includes a method for immobilizing a target material of interest including the steps of: (a) contacting molecules according to Formula (I) immobilized on a solid support, with a solution containing a target material, the target material containing a target sequence of the form (H) choir wherein H is histidine, and i is 4 to 12, preferably 4 to 8, and most preferably 6, under conditions that allow binding of the target material to immobilized molecules according to Formula (I).
- kits including: (a) a molecule according to Formula (I); and (b) a molecule containing a target sequence including an amino acid sequence of the form: (H)bond wherein H is histidine, and i is 4 to 12, preferably 4 to 8, and most preferably 6.
- kits including: (a) a molecule according to Formula (I); and (b) a reagent that promotes the formation of a complex between the molecule according to Formula (I) and a peptide having a target sequence of the form: (H) choir wherein H is histidine, and i is 4 to 12, preferably 4 to 8, and most preferably 6.
- FIG. 1 shows a prior-art model for the binding of neighboring hexahistidine residues to a NTA:Ni 2+ resin.
- FIGS. 2 and 3 show results of fluorescence anisotropy experiments verifying specific interactions between bis-transition-metal-chelate probes according to the invention with a hexahistidine-tagged protein.
- FIG. 4 is a model structure of a DNA F -CAP-His 6 complex showing the position of the fluorescein of DNA F (circle), the position of the hexahistidine tag of each CAP-His 6 promotor (diamond), the distance between fluorescein and the hexahistidine tag of the proximal CAP- His 6 promotor (-55 A), and the distance between fluorescein and the hexahistidine tag of the distal CAP-His 6 promotor (-80 A).
- FIGS. 5 and 6 show results of FRET experiments verifying high-affinity, specificinteractions of bis-transition-metal-chelate probes according to the present invention with a hexahistidinetagged protein.
- FIGS. 7 and 8 show results of FRET experiments verifying stoichiometric interactions of nickel containing probes according to the present invention with the hexahistidine tag.
- a molecule having two transition-metal chelates and a detectable group binds with high affinity and high specificity to oligohistidine target sequences, particularly hexahistidine target sequences.
- a molecule having two transition-metal chelates and a detectable group binds with much higher affinity (more than 10 times higher affinity) and much higher specificity (more than 10 times higher specificity) to oligohistidine target sequences, particularly hexahistidine target sequences, than does a molecule having only a single transition-metal chelate and a detectable group.
- a molecule having two transition-metal chelates and a detectable group can be used to label, detect, and analyze target materials containing, or derivatized to contain, oligohistidine target sequences, particularly hexahistidine target sequences.
- a molecule having two transition-metal chelates and a detectable group can be used in in situ labeling, detection, and analysis of target materials containing, or derivatized to contain, oligohistidine target sequences, particularly hexahistidine target sequences (i.e., direct labeling, detection, and analysis of said target materials-without the need for a subsequent purification step).
- the present invention provides a probe for detecting a target material of interest.
- the probe includes two transition-metal chelates and a detectable group, according to the following general structural Formula (I), and tautomers, salts, and acids thereof:
- Y and Y' are each a transition metal
- R 1 and R 1 are each independently CH(COO " ), CH(COOH), or absent
- R 2 and R 2 are linkers each having a length of about 3.0 to 20 A, and preferably about 3.0 to 15 A
- X is a detectable group.
- the linkers may be linear or branched, may contain aromatic moieties, and may optionally be further substituted.
- "Y" in Formula (I) is a transition metal.
- Y can be any transition metal capable of specific interaction with a oligohistidine tag. Transition metals are those metals having incompletely filled d-orbitals and variable oxidation states.
- Suitable transition metals include: nickel, cobalt, copper, and zinc.
- Y is a divalent transition-metal ion.
- Y is selected from the group consisting of Ni + , Co 2+ , Cu 2+ , and Zn 2+ .
- the chelator is iminodiacetic acid (IDA).
- R 1 is CH(COO-) or CH(COOH)
- the chelator is nitrilotriacteic acid (NTA).
- the chelator is iminodiacetic acid (IDA).
- R 1' is CH(COO-) or CH(COOH)
- the chelator is nitrilotriacetic acid (NTA).
- R 2 and R 2 in Formula (I) are linkers.
- the structures of R 2 and R 2 should permit the two pendant transition-metal chelates to be separated by a distance comparable to the dimensions of a oligohistidine target sequence, particularly a hexahistidine target sequence.
- the structures of R 2 and R 2 should permit the two pendant transition-metal chelates to be separated by about 2.5 to 25 A, and preferably by about 5 to 20 A (distances measured metal-to-metal).
- R and R may be linear or branched, may optionally contain cyclic groups, and may optionally be further substituted.
- R 2 and R 2 may be the same or different.
- R 2 and R 2 are the same.
- R 2 and R 2 may be connected to different atoms of X (preferably two atoms on the same edge or face of X).
- R 2 and R 2 may be connected to the same atom of X.
- R 2 and R 2 may be connected to a single atom, which in turn is connected, directly or through a linker of maximal length 4 A, to X.
- X in Formula (I) is a detectable group.
- Detectable group refers to any chemical moiety that can be detected. Examples of detectable groups include fluorescent moieties, phosphorescent moieties, luminescent moieties, absorbent moieties, photosensitizers, spin labels, radioisotopes, isotopes detectable by nuclear magnetic resonance, paramagnetic atoms, heavy atoms, haptens, crosslinking agents, cleavage agents, and combinations thereof.
- X is detected by monitoring a signal.
- Some signals which may be monitored due to the presence of a detectable group include, for example, fluorescence (fluorescence emission intensity, fluorescence lifetime, fluorescence polarization, fluorescence anisotropy, or fluorescence correlation), luminescence, phosphorescence, absorbance, singlet-oxygen production, electron spin resonance, radioactivity, nuclear magnetic resonance, and X-ray scattering.
- fluorescence fluorescence emission intensity, fluorescence lifetime, fluorescence polarization, fluorescence anisotropy, or fluorescence correlation
- luminescence luminescence
- phosphorescence absorbance
- singlet-oxygen production electron spin resonance
- radioactivity radioactivity
- nuclear magnetic resonance nuclear magnetic resonance
- X-ray scattering X-ray scattering
- X is detected by receptor-binding, protein-protein or protein- nucleic acid crosslinking, or protein or nucleic acid cleavage.
- Preferred detectable groups include fluorescent moieties.
- cyanine fluorescent moieties are used. These include, but are not limited to: Cy3: l-R-2-[3-[l-R-l,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-l-propeny l]-3,3- dimethyl-5-sulfo-3H-indolium, Cy5: l-R-2-[5-[l-R-l,3-dihydro-3,3-dimethyl-5-sulfo-2H- indol-2-ylidene]-l,3- ⁇ enta dienyl]-3,3-dimethyl-5-sulfo-3H-indolium, Cy7: l-R-2-[7-[l-R- l,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]
- cyanine, squaraine, xanthene, xanthanone, and phenoxazine detectable groups fluorescent moieties are described, inter alia, in Southwick et al., 1990, Cytometry 11:418-430; Mujumdar et al., 1993, Bioconjugate Chemistry 4:105-111; Waggoner and Ernst, Fluorescent Regents for Flow Cytometry, Part 1: Principles of Clinical Flow Cytometry (1993) and Haugland, Molecular Probes Handbook of Fluorescent Probes and Research Chemicals, Molecular Inc.
- X may be selected from the following cyanine detectable groups:
- X may be selected from the following squaraine detectable groups:
- U and V are each independently C(R 4 ) 2 , NH, O, S, or (CH) 2 ;
- R 3 and R 3 are each independently H or sulfonate;
- R 4 is H, CH 3 , CH CH 3 , or (CH 2 ) 2 CH 3 ;
- R 5 is absent or is selected from the group consisting of H, an alkyl group, and an aryl group; and
- n' is 0 or an integer of from 1 to 3.
- X may be selected from the following xanthene, xanthanone, and phenoxazine detectable groups:
- R 6 , R 6 , R 6 , R 6 , and R are each independently hydrogen, halogen, hydroxyl, or alkoxyl; and R 7 , when present, is hydrogen, carboxyl, carboxylate or sulfonate.
- One preferred molecule of the present invention includes two pendant transition-metal chelates and a cyanine detectable group according to the following general structural formula:
- Y, Y', R 1 , R 1 , R 2 , and R 2 are as defined previously; wherein U and V are each independently C(R 4 ) 2 , NH, O, S, or (CH) 2 ; R 3 and R 3 are each independently H or sulfonate; R is H, CH 3 , CH 2 CH 3 , or (CH 2 ) 2 CH 3 ; and n is 0 or an integer of from 1 to 6.
- n 1, 2 or 3.
- n is 1, 2, or 3; and R 2 and R 2 are identical and are about 3.0 to 15 A in length.
- n is 1, 2, or 3; R and R 2 are identical and about 3.0 to 15 A in length; and Y and Y' are each Ni 2+
- One preferred molecule of the present invention includes two pendant transition-metal chelates and a cyanine detectable group according to the following general structural formula:
- Y and Y' are as defined previously; U and V are each independently C(R ) , NH, O, S, or (CH) 2 ; R 3 and R 3 are each independently H or sulfonate; R 4 is H, CH 3 , CH 2 CH 3 , or
- n is 0 or an integer of from 1 to 6.
- n is 1, 2, or 3; and Y and Y' are each Ni 2+
- Y and Y' are as defined previously; R 3 and R 3 are each independently H or sulfonate; and n is 1, 2, 3, or 4. In a particularly preferred embodiment, n is 1, 2, or 3; and Y and Y' are each Ni 2+
- detectable groups of the compounds of the present invention there are no particular limitations to the detectable groups of the compounds of the present invention, so long as the ability of the bis-transition-metal-chelate moieties to bind to a target sequence is maintained.
- the point(s) of attachment between the bis-transition-metal- chelate moieties and the detectable group may vary.
- Modifying groups that aid in the use of the bis-transition-metal-chelate derivative may also be incorporated.
- the bis-transition-metal-chelate derivative may be substituted at one or more positions to add a solid-phase binding group or a crosslinking group.
- the bis-transition- metal-chelate derivative preferably is capable of traversing a biological membrane. Smaller molecules are generally able to traverse a biological membrane better than larger derivatives. Bis-transition-metal-chelate derivatives of less than 2000 Daltons are preferable for membrane traversal.
- the polarity of the bis-transition-metal-chelate derivative can also determine the 5 ability of the bis-transition-metal-chelate derivative to traverse a biological membrane.
- a hydrophobic bis-transition-metal-chelate derivative is more likely to traverse a biological membrane.
- the presence of polar groups can reduce the likelihood of a molecule to traverse a biological membrane.
- a bis-transition-metal-chelate derivative that is unable to traverse a biological membrane may be further derivatized by addition of groups that enable
- the bis-transition-metal-chelate derivative may also be derivatized transiently. In such instances, after traversing the membrane, the derivatizing group is eliminated to regenerate the original bis-transition-metal-chelate derivative
- the invention provides methods of synthesis of compounds of the present invention which include coupling of: (a) a synthon which includes a bis-activated-ester derivative of a detectable group; and (b) a synthon which includes an amine or hydrazide derivative of a
- the invention also provides methods of synthesis of non-sulfonated cyanine or squaraine compounds of the present invention which include coupling of: (a) a synthon selected from mono-chelator-functionalized 2,3,3-trimethylindole, mono-chelator- 30 functionalized 2,3,3-trimethylbenzindole, mono-chelator-functionalized 2-methyl-pyridine, mono-chelator-functionalized 2-methyl-benzothiazole, mono-chelator-functionalized 2- methyl-napthothiazole, mono-chelator-functionalized 2-methyl-benzoxazole, and ono- chelator-functionalized 2-methyl-napthoxazole; (b) a synthon, identical or nonidentical to the synthon in (a), selected from the group in (a); and (c) a synthon containing at least one carbon atom; and then adding a transition metal.
- a synthon selected from mono-chelator-functionalized 2,3,3-trimethylindole, mono-chelator- 30
- the invention also provides methods of synthesis of disulfonated cyanine or squaraine compounds of the present invention which include coupling of: (a) a synthon selected from mono-chelator-functionalized 2,3, 3-trimethyl-5-sulfanato-indole, mono-chelator- functionalized 2,3,3-trimethyl-6-sulfanato-benzindole, mono-chelator-functionalized 2- methyl-5-sulfanato-pyridine, mono-chelator-functionalized 2-methyl-5-sulfanato- benzothiazole, mono-chelator-functionalized 2-methyl-6-sulfanato-napthothiazole, mono- chelator-functionalized 2-methyl-5-sulfanato-benzoxazole, and mono-chelator- functionalized 2-methyl-6-sulfanato-napthoxazole; (b) a synthon, identical or nonidentical to the synthon in (a), selected from the group in (a); and (c) a synthon containing at
- the invention also provides methods of synthesis of monosulfonated cyanine or squaraine compounds of the present invention which include coupling of: (a) a synthon selected from mono-chelator-functionalized 2,3,3-trimethylindole, mono-chelator- functionalized 2,3,3-trimethylbenzindole, mono-chelator-functionalized 2-methyl-pyridine, mono-chelator-functionalized 2-methyl-benzothiazole, mono-chelator-functionalized 2- methyl-napthothiazole, mono-chelator-functionalized 2-methyl-benzoxazole, and mono- chelator-functionalized 2-methyl-napthoxazole; (b) a synthon selected from mono-chelator- functionalized 2,3,3-trimethyl-5-sulfanato-indole, mono-chelator-functionalized 2,3,3- trimethyl-6-sulfanato-benzindole, mono-chelator-functionalized 2-methyl-5-sulfanato- pyridine, mono-chelator-functional
- Coupling of the synthons referred to herein can be accomplished in a single step, or in two steps.
- coupling of the reactants (a), (b), and (c) desirably is carried out in a single step.
- coupling of the reactants (a), (b), and (c) desirably is carried out in two steps: i.e., reaction of (a) with (c), followed by reaction of the resultant product with (c); or, alternatively, reaction of (b) with (c), followed by reaction of the resultant product with (a).
- Coupling of the synthons referred to herein can be performed in solution, or with one or more synthons attached to a solid support.
- Coupling of the synthons referred to herein can be performed with the chelator in an unprotected form, or with the chelator in a protected form initially and deprotected thereafter.
- the invention also provides methods of synthesis of xanthene, xanthanone, or phenoxazine compounds of the present invention which include reaction of a xanthene, xanthanone, or phenoxazine detectable group, a secondary-amine derivative of a chelator, and formaldehyde, according to the Mannich reaction (Mannich, C. et al. Arch. Pharm. 250:647, 1912); followed by addition of a transition metal.
- the Mannich reaction referred to herein can be performed with the chelator in an unprotected form, or with the chelator in a protected form initially and deprotected thereafter.
- the invention provides detectable complexes of molecules according to Formula (I) with target sequences.
- Detectable complexes as used herein refer to the association between target amino acid sequences and bis-transition-metal-chelate derivatives according to the invention.
- Suitable target materials include, but are not limited to, polypeptides, and polypeptide mimetics (such as peptide nucleic acid).
- the target material is a polypeptide.
- polypeptide refers to both short chains, commonly referred to as “peptides, “oligopeptides,” or “oligomers,” and to longer chains, generally referred to as “proteins.” Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. Polypeptides may include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well- known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in research literature. Thus “polypeptide” includes peptides, oligopeptides, polypeptides and proteins, all of which terms are used interchangeably herein.
- the target material contains, or is modified to contain, at least one copy of an oligohistidine target sequence, herein referred to interchangeably as the "target sequence” or "tag.”
- the target sequence is generally of the form: (H)j, wherein H is histidine and i is an integer of from 4 to 12 (i.e., SEQ ID NOS. 1-9), preferably 4 to 8, and most preferably 6.
- the target sequence may be inco ⁇ orated at any desired site, or set of sites, within a target material, but preferably is inco ⁇ orated at a site that is (a) accessible and (b) not essential for structure and function of the target material.
- the target sequence preferably is inco ⁇ orated at the N-terminal region, at the C-terminal region, at an internal loop region, at a surface-exposed non-essential loop, at an internal linker region, or at combinations thereof.
- the specific site, or set of sites can be chosen to accommodate the functional requirements of a protein.
- N-terminal modification of chemokines can affect their activity; therefore, in applications with chemokines, either C-terminal modification or internal modification would be preferable. Since labeling is performed at defined, user- selected sites, effects on the activity of target material can be avoided.
- specific activity testing of the tagged vs. the untagged tareget material may be conducted to verify activity. See, for example, Mas et al,. Science, 233:788-790 (1986).
- Target-sequence-containing polypeptides may be generated by total synthesis, partial synthesis, in vitro translation, or in vivo bacterial, archaeal, or eukaryotic production.
- the target sequences and/or target-sequence-containing polypeptides used in the invention are prepared using solid-phase synthesis (see, e.g., Merrifield et al. J. Am. Chem. Soc, 85:2149, (1962) Steward and Young, Solid Phase Peptides Synthesis. Freeman, San Francisco, (1969), and Chan and White, Fmoc Solid Phase Peptide Synthesis - A Practical Approach, Oxford Press (2000)).
- target sequences and/or target-sequence- containing polypeptides used in the invention are prepared using native chemical ligation (Dawson et al, Science, 266, 1994).
- the target sequences and or target-sequence- containing polypeptides are generated by in vivo bacterial, archaeal, or eukaryotic expression of a recombinant nucleic acid sequence encoding the target-sequence-containing polypeptide.
- Methods for the construction of recombinant nucleic acid sequences encoding a tag- containing polypeptide are well known in the art (Sambrook and Russel, Molecular Cloning A Laboratory Manual, 3 rd Ed., Cold Spring Harbor Laboratory, New York (2001), the entirety of which is herein inco ⁇ orated by reference.
- the bis-transition-metal-chelate moieties of the molecules according to Formula (I) bind to the oligohistidine target sequence.
- the transition metals of the bis-transition-metal- chelate moieties bind to imidazole groups of histidines of the oligohistidine target sequence.
- the affinity of the bis-transition-metal-chelate probe for oligohistidine target sequences relates to the presence of two tridentate (where R 1 or R 1 is absent) or tetradentate (where R 1 or R 1 is CH(COO ) or CH(COOH)) transition-metal chelates, each having a transition metal with at least two coordination sites available for interaction with electron-donor groups.
- Oligohistidine target sequences comprising 4 to 12 histidine residues have appropriate electron-donor functionality, size, and flexibility to interact with available coordination sites of the bis-transition-metal-chelate probe, creating a stable linkage therewith.
- transition-metal-chelate probe of the invention in association with a oligohistidine target sequence, in this case a hexahistidine target sequence, is depicted as follows:
- Labeling is accomplished by contacting a bis-transition-metal-chelate molecule according to Formula (I) with a target-sequence-containing target material.
- the bis- transition-metal-chelate molecule may be contacted with a target-sequence-containing target material located in, for example, a test tube, a microtiter-plate well, a cuvette, a flow cell, or a capillary, or immobilized on, for example a surface or other solid support.
- the bis-transition-metal-chelate molecule may be contacted with a target-sequence-containing target material located within a cell, tissue, organ, or organism (in which embodiment, the bis-transition-metal-chelate derivative preferably is capable of traversing an intact biological membrane).
- the bis-transition-metal-chelate molecules according to Formula (I) are used to label target-sequence-containing molecules within cells.
- the bis-transition- metal-chelate molecules of this invention may be introduced into cells by diffusion (for bis- transition-metal-chelate derivatives capable of traversing biological membranes) or by microinjection, electroporation, or vesicle fusion (for any bis-transition-metal-chelate derivative).
- the target-sequence-containing molecules may be introduced into cells by microinjection, electroporation, or vesicle fusion, or by expression of recombinant genes in situ.
- a target-sequence-containing protein produced by expression of a recombinant gene within cells is contacted with a probe of this invention by incubating cells in medium containing the probe.
- cells are imaged using an epi-illumination, confocal, or total-internal-reflection optical microscope with an optical detector, such as a CCD camera, an intensified CCD camera, a photodiode, or a photomultiplier tube, and fluorescence signals are analyzed.
- bis-transition-metal-chelate molecules of the invention may be used in a variety of in vitro and in vivo applications.
- the bis-transition-metal-chelate molecules of the invention may be used in numerous standard assay formats, as are well known in the art.
- assay formats include fluorescence emission intensity, fluorescence polarization (FP), fluorescence anisotropy (FA), fluorescence resonance energy transfer (FRET), fluorescence correlation spectroscopy (FCS), fluorescence-activated cell— or particle— sorting (FACS), x/y-fluorescence scanning (Fluorlmaging), epi-illumination optical microscopy, confocal optical microscopy, total-internal-reflection optical microscopy, absorbance spectroscopy, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), scintillation proximity assay (SPA), autoradiography, and assays formats that involve use of biotin or other hapten inco ⁇ oration to provide a recognition event for binding or immobilization of one or more components.
- the bis-transition-metal-chelate derivatives of the present invention may be used to detect and/or quantify a polypeptide of interest containing, or derivatized to contain, a target sequence.
- the target-sequence-containing polypeptide is incubated with a molecule according to Formula (I) for a time period sufficient to allow labeling thereof.
- Labeled target-sequence-containing polypeptide optionally may be separated from unbound material before the detection step using any method known in the art, and the detectable group X is detected, thereby detecting the polypeptide of interest.
- the target-sequence- containing polypeptide may be included in any material, including, but not limited to, cuvettes, microtiter plates, capillaries, flow cells, test tubes, gels, blots, and biological samples.
- the invention also provides an assay method for monitoring a binding process.
- a first component of a specific reaction pair is labeled with a molecule according to Formula (I) and is reacted with a second component of the pair.
- the reaction can be monitored by monitoring a change in a signal of the detectable group X.
- reaction pairs include, but are not restricted to, antibodies/antigens, hormone/receptor, enzyme/substrate, and protein/an alyte.
- the sample is exposed to light of a first wavelength (able to be absorbed by a fluorescent moiety), and fluorescence-emission intensity is monitored at a second wavelength (emitted by said fluorescent moiety). Fluorescence-emission intensity is dependent on the quantity of the fluorescent moiety and on the local environment of the fluorescent moiety.
- a fluorescence-emission-intensity assay to detect and quantify binding between two molecules, molecule 1 and molecule 2, may be configured as follows: A reaction mixture is prepared by combining molecule 1 labeled with fluorescent moiety X according to the current invention and molecule 2. Complex formation results, directly or indirectly, from a change in the local environment of X, and, correspondingly, in a change in the fluorescence emission intensity of X. The progress of the reaction is monitored by observing the change in fluorescence emission intensity of X. Equilibrium association and dissociation constants may be extracted from the concentration-dependence of the reaction.
- FP or FA assays In a fluorescence-polarization (FP) or fluorescence-anisotropy (FA) assay, a sample is exposed to polarized light of a first wavelength (able to be absorbed by a fluorescent moiety), and fluorescence-emission polarization or anisotropy is monitored at a second wavelength (emitted by said fluorescent moiety). Fluorescence-emission polarization or anisotropy is inversely related to the rotational dynamics, and thus to the size, of said fluorescent moiety (or, if said fluorescent moiety is attached to a molecule or complex, to the rotational dynamics, and thus to the size, of the molecule or complex). FP or FA assays permit detection of reactions that result in changes in size of molecules or complexes, including especially, macromolecule-association and macromolecule-dissociation reactions.
- An FP or FA assay to detect and quantify binding between two molecules, molecule 1 and molecule 2 may be configured as follows: A reaction mixture is prepared by combining molecule 1 labeled with fluorochrome X according to the current invention and molecule 2. Complex formation results in formation of a higher-molecular-weight, higher-FP, higher-FA species. The progress of the reaction is monitored by observing the decrease in FP or FA. Equilibrium association and dissociation constants are extracted from the concentration- dependence of the reaction.
- a further FP or FA assay may be used to detect and quantify proteolytic activity and may be configured as follows: A reaction mixture is prepared by combining a substrate molecule labeled with fluorochrome X according to the present invention and a sample containing a proteolytic enzyme. Cleavage of the substrate molecule by the proteolytic enzyme results in the production of lower-molecular- weight, lower-FP, lower-FA fragments. The progress of the reaction is monitored by observing the decrease in FP or FA.
- Fluorescence resonance energy transfer is a physical phenomenon that permits measurement of distance). FRET occurs in a system having a fluorescent probe serving as a donor and a second fluorescent probe serving as an acceptor, where the emission spectrum of the donor overlaps the excitation spectrum of the acceptor. In such a system, upon excitation of the donor with light of the donor excitation wavelength, energy can be transferred from the donor to the acceptor, resulting in excitation of the acceptor and emission at the acceptor emission wavelength. FRET readily can be detected— and the efficiency of FRET readily can be quantified— by exciting with light of the donor excitation wavelength and monitoring emission of the donor, emission of the acceptor, or both.
- the efficiency of energy transfer, E is a function of the Forster parameter, R 0 , and of the distance between the donor and the acceptor, R:
- n is the refractive index of the medium
- ⁇ > D is the donor quantum yield in the absence of the acceptor
- K is the orientation factor relating the donor acceptor transition dipoles
- J is the spectral overlap integral of the donor emission spectrum and the acceptor excitation spectrum.
- FRET Fluorescence Activated FRET is useful over distances of about 1 nm to about 15 nm, which are comparable to the dimensions of biological macromolecules and macromolecule complexes. Thus, FRET is a useful technique for investigating a variety of biological phenomena that produce changes in molecular proximity. When FRET is used as a detection mechanism, colocalization of proteins and other molecules can be imaged with spatial resolution beyond the limits of conventional optical microscopy.
- a FRET assay to detect and quantify binding between two molecules, molecule 1 and molecule 2 may be configured as follows: A reaction mixture is prepared by combining molecule 1 labeled with a molecule according to Formula (I) where detectable group X is a fluorescent moiety and molecule 2 is labeled with a fluorescent moiety Y or a chrompohore Y, wherein X and Y are able to participate in FRET. Complex formation results in increased proximity between X and Y, and, correspondingly, in increased FRET. The progress of the reaction is monitored by observing the increase in FRET. Equilibrium association and dissociation constants may be extracted from the concentration-dependence of the reaction.
- a FRET assay to detect and quantify proteolytic activity may be configured as follows: A reaction mixture is prepared by combining a) a substrate molecule labeled at site 1 with Formula (I) wherein detectable group X is a fluorescent moiety and labeled at site 2 with fluorochrome Y, wherein sites 1 and 2 are on opposite sides of the proteolytic-cleavage site, and wherein X and Y are able to participate in FRET, and b) a sample containing a proteolytic enzyme. Cleavage of the substrate molecule by the proteolytic enzyme results in decreased proximity between X and Y and, correspondingly, in decreased FRET. The progress of the reaction is monitored by observing the decrease in FRET.
- a FRET assay to detect conformation change within molecule 1 induced upon interaction with molecule 2 may be configured as follows: A reaction mixture is prepared by combining (a) molecule 1 labeled at one site with fluorochrome X according to the current invention and labeled at another site with fluorochrome Y, wherein X and Y are able to participate in FRET, and (b) molecule 2. Conformation change within molecule 1 induced upon interaction with molecule 2 results in a change in proximity between X and Y, and, correspondingly, a change in FRET. The progress of the reaction is monitored by observing the change in FRET.
- a FRET assay to measure the distance between two sites, 1 and 2, within a molecule of interest may be configured as follows: the molecule of interest is labeled at site 1 with fluorochrome X according to the current invention and is labeled at site 2 with fluorochrome Y, wherein X and Y are able to participate in FRET; fluorescence excitation and emission spectra are collected for X and Y; and the distance, R, is calculated as described supra.
- Fluorescence emission intensity, lifetime, polarization, aniosotropy and FRET are further described in the following references: Brand, L. and Johnson, M.L., Eds., Fluorescence Spectroscopy (Methods in Enzymology, Volume 278), Academic Press (1997), Cantor, CR. and Schimmel, P.R., Biophysical Chemistry Part 2, W.H. Freeman (1980) pp. 433 ⁇ 4-65. Dewey, T.G., Ed., Biophysical and Biochemical Aspects of Fluorescence
- Fluorescence imaging using epi-illumination, confocal, or total-internal-reflection optical microscopy permits characterization of the quantities, locations, and interactions of fluorochrome-labeled target materials within cells. All fluorescence observables that can be analyzed in vitro— emission intensity, emission lifetime, fluorescence correlation, FP/FA, and FRET-also can be analyzed in cells (See Nakanishi et al. Anal. Chem. 73:2920-2928 (2001); Maiti, S. et al. Proc. Natl. Acad. Sci. USA 94: 11753-11757 (1997); Eigen and Rigler, Proc. Natl. Acad. Sci. USA 91:5740-5747 (1994) for example of uses of fluorescence in cells).
- the bis-transition-metal-chelate derivatives of this invention may be used to label target-sequence-containing molecules within cells.
- the bis-transition-metal-chelate derivatives of this invention may be introduced into cells by diffusion (for bis-transition- metal-chelate derivatives capable of traversing biological membranes) or by microinjection, electroporation, or vesicle fusion (for any bis-transition-metal-chelate derivative).
- the target- sequence-containing molecules may be introduced into cells by microinjection, electroporation, or vesicle fusion, or by expression of recombinant genes in situ.
- a target-sequence-containing protein produced by expression of a recombinant gene within cells is contacted with a bis-transition-metal-chelate derivative of this invention by incubating cells in medium containing the bis-transition-metal-chelate derivative.
- the cells are imaged using an epi-illumination, confocal, or total-internal-reflection optical microscope with an optical detector, such as a CCD camera, an intensified CCD camera, a photodiode, or a photomultiplier tube, and fluorescence signals are analyzed.
- the fluorescent molecules of the present invention also can be used, in vitro or in vivo, in single-molecule fluorescence assays with single-molecule detection, wherein fluorescence emission intensity, fluorescence correlation, FP/FA, or FRET is analyzed from individual single molecules.
- the fluorescent molecules of the present invention also can be used, in vitro or in vivo, in fluorescence assays with "multiplex" detection, wherein a plurality of different fluorescent molecules are attached to a plurality of different primary molecules, molecule la, lb, ...In, with each primary molecule being specific for a different secondary component, 2a, 2b, ...2n, in order to monitor a plurality of reactions between primary molecules and secondary molecules in a single reaction mixture.
- each of the primary molecules is separately labeled with a fluorochrome having a different, distinguishable excitation and/or emission wavelength.
- the primary molecules are then reacted, as a group, with the secondary molecules, as a group, and fluorescence is monitored at each of different, distinguishable excitation and/or emission wavelengths.
- the present invention is compatible with fluorochromes having different, distinguishable excitation and emission wavelengths (see, e.g., Table 1 for excitation maxima and emission maxima of derivatives of Cy3, Cy5, and Cy7 in Examples), makes the invention particularly important for applications involving multiplex detection.
- fluorochromes and chromophores suitable for use in assays above, in conjunction with the molecules of the invention are presented in Haugland R. P. Handbook of Fluorescent Probes and Research Chemicals, Molecular Probes, sixth edition (1996), ISBN 0-9652240-0-7 (Spence, MTZ, ed).
- Said fluorochromes and chromophores can be inco ⁇ orated into polypeptides and other molecules of interest by any suitable method, many of which are well known in the art, including, but not limited to, chemical synthesis, enzymatic synthesis, ribosomal synthesis, chemical ligation, chemical modification, and hapten binding (see Haugland R. P. Handbook of Fluorescent Probes and Research Chemicals, supra).
- fusions of autofluorescent proteins, such as green fluorescent protein, to a polypeptide of interest can be encoded as nucleic-acid fusion constructs, produced in cells, and analyzed in cells or in vitro.
- the methods of the invention may be used in many areas of biology and biological research including drug screening, diagnostics and academic research.
- bis-transition-metal-chelate molecules of the invention may be used for immobilization and or affinity-purification of target-sequence- containing molecules.
- Immobilization may be accomplished by: (a) covalently attaching a bis-transition- metal-chelate derivative to a surface or other solid support (via detectable group X or via a linker); (b) contacting the resulting bis-transition-metal-chelate-derivative-containing surface or other solid support with a solution containing a target-sequence-containing target material; and (c) optionally washing the surface or the solid support to remove unbound material.
- Affinity purification may be accomplished by: (a) covalently attaching a bis- transition-metal-chelate derivative to a surface or other solid support, (b) contacting the resulting bis-transition-metal-chelate-derivative-containing surface or other solid support with a solution containing a target-sequence-containing molecule, (c) optionally washing the surface or other solid support to remove unbound material, and (d) eluting the target- sequence-containing molecule with a low-molecular-weight monothiol (e.g., ⁇ - mercaptoethanol) or, preferably, a low-molecular-weight dithiol (e.g., dithiothreitol or ethanedithiol).
- a low-molecular-weight monothiol e.g., ⁇ - mercaptoethanol
- dithiol e.g., dithiothreitol or ethanedithiol
- the invention also provides a kit including a molecule according to Formula (I) and a target material including a target sequence of the form: (H)j, wherein H is histidine and i is an integer of from 4 to 12 (i.e., SEQ ID NOS. 1-9), preferably 4 to 8, and most preferably 6.
- the invention also provides a kit.
- the kit includes a molecule according to Formula
- N-(5-amino-l-carboxypentyl)iminodiacetic acid (Dojindo; 26 mg, 80 ⁇ mol) was dissolved in 1.6 ml 0.1M sodium carbonate and was added to Cy3 bis-succinimidyl-ester ("Cy3 Reactive Dye” from Amersham-Pharmacia Biotech).
- NiCl 2 (Aldrich; 350 nmol of NiCl 2 in 3 ⁇ l of 0.01N HC1) was added to (NTA) 2 -Cy3 (70 nmol in 2 ml water), and the solution was brought to pH 7 by addition of 0.8 ml 50 mM sodium acetate (pH 7), 200 mM NaCl. Following reaction for 30 min. at 25°C in the dark, the product was purified using a Sep-Pak C18 cartridge ((Millipore; procedure as above) and dried. ES-MS: m/e 1316.8 (calculated 1315.7).
- Ni 2+ content [determined by performing analogous reaction with 63 NiCl 2 (New England Nuclear) and quantifying reactivity in product by scintillation counting in Scinti verse II (Fischer)]: 1.4 mol Ni 2+ per mol. Spectroscopic properties are reported in Table 1.
- N-(5-amino-l-carboxypentyl)iminodiacetic acid (Dojindo; 40 mg; 125 ⁇ mol) was dissolved in 0.8 ml 0.1M sodium carbonate and was added to Cy5 bis-succinimidyl-ester ("Cy5 Reactive Dye” Amersham-Pharmacia Biotech; 800 nmol).
- NiCl 2 (Aldrich; 90 nmol in 1 ⁇ l of 0.01 N HC1) was added to (NTA) 2 -Cy5 (30 mmol in 1 ml water), and the solution was bought to pH 7 by addition of 0.5 ml 50 mM sodium acetate (pH 7), 70 mM NaCl. Following reaction for 30 min. at 25°C in the dark, the product was purified using a Sep-Pak C18 cartridge ((Millipore; procedure as above) and dried. ES- MS: m/e 1341.0 (calculated 1341.7). Spectroscopic properties are reported in Table 1.
- Plasmid pAKCRP-His 6 encodes CAP-His 6 under the control of bacteriophage T7 gene 10 promotor.
- Plasmid AKCRP-His 6 was constructed from plasmid pAKCRP (as described in Kapanidis, A. et al., J. Mol. Biol. 312:453-468 (2001) by using site-directed mutagenesis (as described in Kukel, et al., J. Meths. Enzymol, 204:125-138 (1991)) to insert six His codons (CAC-CAC-CAC-CAC-CAC-CAC-CAC) after codon 209 of the c ⁇ gene.
- the cell pellet was re-suspended in 15 ml buffer A [20 M Tris-HCl (pH 7.9), 500 mM NaCl, 5 mM imidazole], cells were lysed by sonication, and the lysate was cleared by centrifugation (30,000 x g; 30 min. at 4°C).
- the sample was adjusted to 15 ml with buffer A, adsorbed onto 2 ml Ni 2+ -NTA agarose (Qiagen) in buffer A, washed with 12 ml buffer A containing 20 mM imidazole, and eluted with 6 x 1 ml buffer A containing 200 mM imidazole.
- Affinity and specificity of association of the probe with target material were evaluated using fluorescence anisotropy assays (methods as in Jameson and Dwyer, Methods Enzymol, 246:283-300 (1995)). Formation of a complex of the probe with a tagged protein was detected as an increase in fluorescence anisotropy, A, arising from the increase in molecular size and corresponding decrease in rotational dynamics.
- Reaction mixtures [200 ⁇ l, in 100 ⁇ l quartz micro-cuvettes (Starna)] contained 50 nM of (Ni 2+ -NTA) -Cv3 or (Ni 2+ -NTA)?-Cy5 in buffer C [40 mM Tris-HCl (pH 8), 100 mM NaCl, 1 mM dithiothreitol, 0.5 mM imidazole, 0.2 mM cAMP, 100 ⁇ g/ml bovine serum albumin, and 5% glycerol].
- Reaction mixtures were titrated with 0-3 ⁇ M CAP-His 6 (or CAP) by successive addition of 0.5-4 ⁇ l aliquots of 2-4 ⁇ M CAP-His 6 (or CAP) in the same buffer. Fluorescence anisotropy was determined at the start of the titration and 5 min after each successive addition in the titration. All solutions were maintained at 25°C.
- Fluorescence measurements were performed using a commercial steady-state fluorescence instrument (QM-1, PIT) equipped with T-format Glan-Thompson polarizers (PTI). Excitation wavelengths were 530 nm for (Ni 2+ -NTA)?-Cv3 and 630 nm for (Ni 2+ - NTA) 2 -Cy5; emission wavelengths were 570 nm for (Ni -NTA)?-Cy3 and 670 nm for (Ni NTA) 2 -Cy5. Slit widths were lOmn. Fluorescence emission intensities were corrected for background by subtraction of fluorescence emissions intensities for control reactions containing identical concentrations of CAP-His 6 or CAP but not containing probe.
- FIG. 3 a graphical representation is shown of titration of (NTA) 2 - Cy5 with CAP-His 6 is shown (filled circles).
- NTA N-(n-phenyl) 7-Cy5
- DNA F 53 base pair fluorescein-labelled DNA fragment containing the consensus DNA site for CAP (fluorescein inco ⁇ orated at position -9 relative to the consensus DNA site for CAP) was prepared as described in Ebright, R. et al., J. Mol. Biol. 312:453-468 (2001).
- FRET Assays Standard TitrationsReaction mixtures [200 ⁇ l, in 50 ⁇ l quartz micro-cuvettes (Starna)] contained 5 nM DNA F and 50 nM CAP-His 6 (or CAP) in buffer C. Reaction mixtures were titrated with 0-3.2 ⁇ M 2a or 2b by successive addition of 0.3-1.2 ⁇ l aliquots of 30-300 ⁇ M of (Ni 2+ -NTA) 2 -Cy3 or (Ni 2+ -NTA) 2 -Cy5 in the same buffer. Fluorescence anisotropy was determined at the start of the titration and 5 min after each successive addition in the titration. All solutions were maintained at 25°C.
- Fluorescent emission intensities, F were measured using a commercial steady-state fluorescence instrument (QM-1, PTI) equipped with T-format Glan-Thompson polarizers (PTI) set at 54.7° ("magic angle").
- Excitation wavelength was 480 nm; emission wavelength range were 500-600 nm (titrations with (Ni 2+ -NTA) 2 -Cy3) or 500-700 (titrations with (Ni 2+ :NTA) 2 -Cy5; excitation slit width was 10 nm; emission slit width was 15 nm.
- Fluorescence emission intensities were corrected for background (by subtraction of fluorescence emission intensities for control reaction mixtures containing identical concentrations of (Ni 2+ -NTA) 2 -Cy3 or (Ni 2+ -NTA) 2 -Cy5, but not containing CAP-His 6 or CAP) and for dilution.
- FIG. 5 a graphical representation of results of titration of the (CAP- His 6 )-DNA F complex with (Ni 2+ -NTA) 2 -Cy3 is shown (filled circles).
- Specific interaction between the (CAP-His 6 )-DNA F complex and (Ni 2+ -NTA)?-Cy3 is evidenced by a large, saturable increase in FRET.
- Specificity of interaction is evidenced by the absence of a significant increase in fluorescence anisotropy in a control titration with the CAP-DNA complex (open circles; (>95% specificity).
- FIG. 6 a graphical representation of results of titration of the (CAP-
- Donor-acceptor distances were determined using the measured efficiencies of FRET at saturation, E sat (0.45 for titration with (Ni 2 ⁇ I NTA) 2 -Cy5; 0.25 for titration (Ni 2+ -NTA)?-Cy5; see FIGS. 5, 6), and the measured Forster parameters, R 0 :
- n is the refractive index of the medium (1.4 for dilute protein solutions )
- K is the orientation factor relating the donor emission dipole and acceptor dipole [approximated as 2/3 due to the low fluorescent anisotropy of the donor]
- J is the spectral overlap integral of the donor emission spectrum and the acceptor excitation spectrum:
- F D ( ⁇ ) is the normalized corrected emission spectrum of donor
- 8 A ( ⁇ ) is the molar extinction coefficient of acceptor
- ⁇ is the wavelength
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002367810A AU2002367810A1 (en) | 2002-03-28 | 2002-11-12 | Bis-transition-metal-chelate-probes |
EP02807321A EP1506402A2 (en) | 2002-03-28 | 2002-11-12 | Bis-transition-metal-chelate-probes |
CA002488819A CA2488819A1 (en) | 2002-03-28 | 2002-11-12 | Bis-transition-metal-chelate-probes |
US10/665,227 US6919333B2 (en) | 2002-11-12 | 2003-09-17 | Bis-transition-metal-chelate probes |
US10/946,786 US7371745B2 (en) | 2002-03-28 | 2004-09-21 | Bis-transition-metal-chelate probes |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36777502P | 2002-03-28 | 2002-03-28 | |
US60/367,775 | 2002-03-28 | ||
US41026702P | 2002-09-13 | 2002-09-13 | |
US60/410,267 | 2002-09-13 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/665,227 Continuation-In-Part US6919333B2 (en) | 2002-03-28 | 2003-09-17 | Bis-transition-metal-chelate probes |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003091689A2 true WO2003091689A2 (en) | 2003-11-06 |
WO2003091689A3 WO2003091689A3 (en) | 2004-12-23 |
Family
ID=29272981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/036180 WO2003091689A2 (en) | 2002-03-28 | 2002-11-12 | Bis-transition-metal-chelate-probes |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1506402A2 (en) |
AU (1) | AU2002367810A1 (en) |
CA (1) | CA2488819A1 (en) |
WO (1) | WO2003091689A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006013042A2 (en) | 2004-08-05 | 2006-02-09 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Multivalent chelators for modifying and organizing of target molecules |
US7282373B2 (en) | 2004-12-23 | 2007-10-16 | Rutgers, The State University Of New Jersey | Ultra-high specificity fluorescent labeling |
US7381572B2 (en) | 2004-12-23 | 2008-06-03 | Rutgers, The State University Of New Jersey | Reagents and procedures for multi-label high-specificity labeling |
JPWO2008153223A1 (en) * | 2007-07-31 | 2010-08-26 | 国立大学法人大阪大学 | Composition for measuring binding affinity between nucleic acid and test substance and use thereof |
US20110015139A1 (en) * | 2008-03-19 | 2011-01-20 | he Henry M. JAckson Foundation for the Advancement of Military Medicine, Inc. | Histidine related compounds for identifying and blocking amyloid beta ion channels |
JP2011046662A (en) * | 2009-08-28 | 2011-03-10 | Fujifilm Corp | Near infrared fluorescent imaging agent |
US8883962B2 (en) | 2012-01-13 | 2014-11-11 | Massachusetts Institute Of Technology | Zinc-responsive peptides, and methods of use thereof |
CN115108966A (en) * | 2022-06-23 | 2022-09-27 | 西南医科大学 | Benzoindole squarylium cyanine metal ion probe and preparation method and application thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4761481A (en) * | 1985-03-18 | 1988-08-02 | Baxter Travenol Laboratories, Inc. | Substituted pyridine derivatives |
WO1993011433A1 (en) * | 1991-12-05 | 1993-06-10 | Wallac Oy | Luminescent lanthanide chelates |
WO2000009169A1 (en) * | 1998-08-14 | 2000-02-24 | K.U. Leuven Research & Development | Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical |
WO2000047548A1 (en) * | 1999-02-08 | 2000-08-17 | Australian Membrane And Biotechnology Research Institute | Improved compounds for protein binding |
WO2001052744A1 (en) * | 2000-01-18 | 2001-07-26 | Mallinckrodt Inc. | Hydrophilic cyanine dyes |
WO2001064708A1 (en) * | 2000-02-29 | 2001-09-07 | Bracco Imaging S.P.A. | Bile acids conjugates with metal ion chelates and the use thereof |
WO2001081365A2 (en) * | 2000-04-24 | 2001-11-01 | Sigma-Aldrich Co. | Metal chelating compositions |
WO2002038546A1 (en) * | 2000-11-08 | 2002-05-16 | K.U. Leuven Research & Development | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them |
WO2002059076A1 (en) * | 2001-01-26 | 2002-08-01 | Schering Aktiengesellschaft | Method for producing dtpa monoamides |
-
2002
- 2002-11-12 CA CA002488819A patent/CA2488819A1/en not_active Abandoned
- 2002-11-12 EP EP02807321A patent/EP1506402A2/en not_active Withdrawn
- 2002-11-12 WO PCT/US2002/036180 patent/WO2003091689A2/en not_active Application Discontinuation
- 2002-11-12 AU AU2002367810A patent/AU2002367810A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4761481A (en) * | 1985-03-18 | 1988-08-02 | Baxter Travenol Laboratories, Inc. | Substituted pyridine derivatives |
WO1993011433A1 (en) * | 1991-12-05 | 1993-06-10 | Wallac Oy | Luminescent lanthanide chelates |
WO2000009169A1 (en) * | 1998-08-14 | 2000-02-24 | K.U. Leuven Research & Development | Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical |
WO2000047548A1 (en) * | 1999-02-08 | 2000-08-17 | Australian Membrane And Biotechnology Research Institute | Improved compounds for protein binding |
WO2001052744A1 (en) * | 2000-01-18 | 2001-07-26 | Mallinckrodt Inc. | Hydrophilic cyanine dyes |
WO2001064708A1 (en) * | 2000-02-29 | 2001-09-07 | Bracco Imaging S.P.A. | Bile acids conjugates with metal ion chelates and the use thereof |
WO2001081365A2 (en) * | 2000-04-24 | 2001-11-01 | Sigma-Aldrich Co. | Metal chelating compositions |
WO2002038546A1 (en) * | 2000-11-08 | 2002-05-16 | K.U. Leuven Research & Development | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them |
WO2002059076A1 (en) * | 2001-01-26 | 2002-08-01 | Schering Aktiengesellschaft | Method for producing dtpa monoamides |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006013042A2 (en) | 2004-08-05 | 2006-02-09 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Multivalent chelators for modifying and organizing of target molecules |
US7282373B2 (en) | 2004-12-23 | 2007-10-16 | Rutgers, The State University Of New Jersey | Ultra-high specificity fluorescent labeling |
US7381572B2 (en) | 2004-12-23 | 2008-06-03 | Rutgers, The State University Of New Jersey | Reagents and procedures for multi-label high-specificity labeling |
US8741659B2 (en) | 2007-07-31 | 2014-06-03 | Osaka University | Composition for measuring the binding affinity between nucleic acid and test substance, and use thereof |
JPWO2008153223A1 (en) * | 2007-07-31 | 2010-08-26 | 国立大学法人大阪大学 | Composition for measuring binding affinity between nucleic acid and test substance and use thereof |
JP4533981B2 (en) * | 2007-07-31 | 2010-09-01 | 国立大学法人大阪大学 | Composition for measuring binding affinity between nucleic acid and test substance and use thereof |
US20110015139A1 (en) * | 2008-03-19 | 2011-01-20 | he Henry M. JAckson Foundation for the Advancement of Military Medicine, Inc. | Histidine related compounds for identifying and blocking amyloid beta ion channels |
US8476240B2 (en) * | 2008-03-19 | 2013-07-02 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Histidine related compounds for identifying and blocking amyloid beta ion channels |
JP2011046662A (en) * | 2009-08-28 | 2011-03-10 | Fujifilm Corp | Near infrared fluorescent imaging agent |
US8883962B2 (en) | 2012-01-13 | 2014-11-11 | Massachusetts Institute Of Technology | Zinc-responsive peptides, and methods of use thereof |
WO2013106819A3 (en) * | 2012-01-13 | 2015-06-18 | Massachusetts Institute Of Technology | Zinc-responsive peptides, and methods of use thereof |
CN115108966A (en) * | 2022-06-23 | 2022-09-27 | 西南医科大学 | Benzoindole squarylium cyanine metal ion probe and preparation method and application thereof |
CN115108966B (en) * | 2022-06-23 | 2023-06-09 | 西南医科大学 | Benzoindole squaraine metal ion probe and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1506402A2 (en) | 2005-02-16 |
AU2002367810A8 (en) | 2003-11-10 |
CA2488819A1 (en) | 2003-11-06 |
WO2003091689A3 (en) | 2004-12-23 |
AU2002367810A1 (en) | 2003-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7282373B2 (en) | Ultra-high specificity fluorescent labeling | |
US7371745B2 (en) | Bis-transition-metal-chelate probes | |
JP5008044B2 (en) | Energy transfer assays and reagents | |
JP4790598B2 (en) | Meso-substituted cyanine dye labeling reagent | |
Gonçalves | Fluorescent labeling of biomolecules with organic probes | |
US8227621B2 (en) | Cyanine dyes and methods of use | |
JP4943156B2 (en) | Cyanine dye labeling reagent | |
US6686145B1 (en) | Rigidized trimethine cyanine dyes | |
KR20080038183A (en) | Labeling dye for detecting biomolecule, labeling kit, and method for detecting biomolecule | |
US7381572B2 (en) | Reagents and procedures for multi-label high-specificity labeling | |
EP1506402A2 (en) | Bis-transition-metal-chelate-probes | |
US10557852B2 (en) | Fluorescent molecular sensor for targeting changes in protein surfaces, and methods of use thereof | |
US6919333B2 (en) | Bis-transition-metal-chelate probes | |
US7141655B2 (en) | Reagents and procedures for high-specificity labeling | |
US20030211454A1 (en) | Detection reagent | |
WO2008018129A1 (en) | Method of detecting protein and fluorescent dye to be used therefor | |
EP1322664A2 (en) | Dye-labelled peptide and its diagnostic use | |
WO2004051270A2 (en) | Labeling methodology comprising oligopeptides | |
US20040023408A1 (en) | Site-specific labelling of proteins using cyanine dye reporters | |
JP2005534739A (en) | Site-specific labeling of proteins using a cyanine dye reporter | |
WO2004065548A2 (en) | Synthetic molecules for labeling histidine-rich proteins | |
JP2005534738A (en) | Site-specific labeling of proteins using acridone and quinacridone lifetime dyes | |
Dattelbaum | Luminescent probes for the detection of glutamine and protein hydrodynamics | |
Wu | Design, syntheses and applications of fluorescent dyes | |
CS273630B2 (en) | Method of resorufine's derivatives production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 10665227 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002807321 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2488819 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2002807321 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002807321 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |